On March 7, 2023 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, reported that the Company plans to participate in a fireside chat and host one-on-one meetings at two investor conferences (Press release, Cyclacel, MAR 7, 2023, View Source [SID1234628273]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oppenheimer 33rd Annual Healthcare Conference:

Location: Virtual
Format: Fireside chat and one-on-one meetings
Date: March 13-15, 2023
Fireside chat: March 13, 10:00am ET
Presenter: Spiro Rombotis
Webcast: Link
35th Annual Roth Conference:

Location: Dana Point, CA
Format: Fireside chat and one-on-one meetings
Date: March 12-14, 2023
Fireside chat: March 13, 3:00pm PT
Presenter: Paul McBarron
Webcast: Link

About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel’s strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.